Core Viewpoint - The company has received approval from the National Medical Products Administration for clinical trials of HRS-4729 injection, a novel triple receptor agonist aimed at improving metabolic regulation and weight loss [1] Group 1: Product Development - HRS-4729 injection is a self-developed peptide drug targeting GLP-1R, GIPR, and GCGR receptors, which enhances energy expenditure and lipid metabolism compared to dual-target drugs [1] - The drug aims to suppress appetite and promote fat oxidation, potentially leading to better weight loss and reduced liver fat [1] - As of now, there are no similar products approved for market release domestically or internationally [1] Group 2: Financial Investment - The cumulative research and development investment for HRS-4729 injection has reached approximately 39.62 million yuan [1]